Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Olaparib
Olaparib is a specialized medication prescribed for maintenance treatment in patients diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is particularly beneficial for individuals with specific types of inherited (germline) or acquired (somatic) abnormalities in the BRCA gene.
Uses of Olaparib
Olaparib is used for:
Maintenance therapy in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have responded to initial treatment.
Treatment of patients with BRCA-mutated cancers, including both germline and somatic mutations.
Benefits of Olaparib
Delays disease progression and prolongs progression-free survival in patients with BRCA-mutated cancers.
Reduces the risk of cancer recurrence after initial therapy.
Offers a well-tolerated oral formulation, enhancing patient convenience and compliance with treatment.
Mechanism of Action of Olaparib
Olaparib belongs to a class of medications known as poly ADP-ribose polymerase (PARP) inhibitors. It works by inhibiting PARP enzymes, which are involved in repairing damaged DNA in cells. In cancers with BRCA mutations, olaparib prevents DNA repair mechanisms, leading to synthetic lethality and selective cancer cell death.